Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniela Willen

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Frontiers in Bioscience : a Journal and Virtual Library|May 9, 2007
TRAIL: a multifunctional cytokineUta Schaefer, Oksana Voloshanenko, Daniela Willen, et al.
European Journal of Drug Metabolism and Pharmacokinetics|September 19, 2019
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Atacicept in a Randomized Trial in Healthy Caucasian and Japanese SubjectsDaniela Willen, Wolfgang Uhl, Peter Wolna, et al.
Cornea|December 28, 2020
A Randomized Clinical Study (SEECASE) to Assess Efficacy, Safety, and Tolerability of NOV03 for Treatment of Dry Eye DiseaseJoseph Tauber, David L Wirta, Kenneth Sall, et al.
Frontiers in Immunology|December 19, 2022
Kinetics of free and ligand-bound atacicept in human serumMahya Eslami, Daniela Willen, Orestis Papasouliotis, et al.
British Journal of Pharmacology|July 30, 2019
No interactions between heparin and atacicept, an antagonist of B cell survival cytokinesChristine Kowalczyk-Quintas, Daniela Willen, Laure Willen, et al.
JAMA Ophthalmology|April 9, 2026
Interleukin 6 Inhibition With Vamikibart for Uveitic Macular Edema: The Phase 1 DOVETAIL Nonrandomized Clinical TrialSumit Sharma, Phoebe Lin, Allen Hu, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Frontiers in Bioscience : a Journal and Virtual Library|May 9, 2007
TRAIL: a multifunctional cytokineUta Schaefer, Oksana Voloshanenko, Daniela Willen, et al.
European Journal of Drug Metabolism and Pharmacokinetics|September 19, 2019
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Atacicept in a Randomized Trial in Healthy Caucasian and Japanese SubjectsDaniela Willen, Wolfgang Uhl, Peter Wolna, et al.
Cornea|December 28, 2020
A Randomized Clinical Study (SEECASE) to Assess Efficacy, Safety, and Tolerability of NOV03 for Treatment of Dry Eye DiseaseJoseph Tauber, David L Wirta, Kenneth Sall, et al.
Frontiers in Immunology|December 19, 2022
Kinetics of free and ligand-bound atacicept in human serumMahya Eslami, Daniela Willen, Orestis Papasouliotis, et al.
British Journal of Pharmacology|July 30, 2019
No interactions between heparin and atacicept, an antagonist of B cell survival cytokinesChristine Kowalczyk-Quintas, Daniela Willen, Laure Willen, et al.
JAMA Ophthalmology|April 9, 2026
Interleukin 6 Inhibition With Vamikibart for Uveitic Macular Edema: The Phase 1 DOVETAIL Nonrandomized Clinical TrialSumit Sharma, Phoebe Lin, Allen Hu, et al.
Pageof 1